AI English summary of an SEC filing — figures as filed
Viatris VTRSViatris reported total revenues of $3.58 billion for the 3 months ended June 30, 2025, compared to $3.80 billion for the comparable prior year period, representing a decrease of $214.5 million, or 6%. Net sales decreased by $216.9 million, or 6%, to $3.57 billion.
Key points
AI summaryViatris reported total revenues of $3.58 billion for the 3 months ended June 30, 2025, compared to $3.80 billion for the comparable prior year period, representing a decrease of $214.5 million, or 6%. Net sales decreased by $216.9 million, or 6%, to $3.57 billion.
The company said net sales decreased by approximately $212.2 million, or 6%, due to the inclusion of net sales in the prior year period related to divestitures that closed during 2024. The favorable impact of foreign currency translation was approximately $61.5 million, or 2%. On a constant currency basis, net sales from the remaining business decreased by approximately $66.2 million, or 2%.
Other expense, net for Q2 2025 totaled $333.5 million, compared to $6.1 million for the comparable prior year period. The company cited a loss of $284.0 million recorded in the current year period as a result of changes in the fair value of the CCPS in Biocon Biologics as a factor in the increase.
Viatris said cash and cash equivalents totaled $566.4 million as of June 30, 2025. The company has access to $3.5 billion under the 2024 Revolving Facility and up to $600 million under the Receivables Facility, and as of that date had no borrowings outstanding under either facility.
Key figures
Quarter ended June 30, 2025
- Revenue
- $3.6B
- Operating income
- $233M
- EPS
- −$0.27
- Gross profit
- $1.3B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q2 2025 Total Revenues $3.58 billion
Viatris reported total revenues of $3.58 billion for the 3 months ended June 30, 2025, compared to $3.80 billion for the comparable prior year period, representing a decrease of $214.5 million, or 6%. Net sales decreased by $216.9 million, or 6%, to $3.57 billion.
Source · Based on the MD&A text of the filing
Constant Currency Net Sales Decrease $66.2 million
The company said net sales decreased by approximately $212.2 million, or 6%, due to the inclusion of net sales in the prior year period related to divestitures that closed during 2024. The favorable impact of foreign currency translation was approximately $61.5 million, or 2%. On a constant currency basis, net sales from the remaining business decreased by approximately $66.2 million, or 2%.
Source · Based on the MD&A text of the filing
Biocon Biologics CCPS Fair Value Loss
Other expense, net for Q2 2025 totaled $333.5 million, compared to $6.1 million for the comparable prior year period. The company cited a loss of $284.0 million recorded in the current year period as a result of changes in the fair value of the CCPS in Biocon Biologics as a factor in the increase.
Source · Based on the MD&A text of the filing
Cash $566.4 million as of June 30, No Borrowings
Viatris said cash and cash equivalents totaled $566.4 million as of June 30, 2025. The company has access to $3.5 billion under the 2024 Revolving Facility and up to $600 million under the Receivables Facility, and as of that date had no borrowings outstanding under either facility.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…